Rejuvenate Skin GHKCu Troches Peptides for Advanced Regeneration & Longevity Support Unlock the Power of GHK-Cu for Cellular Repair & Vitality GHK-Cu is a
Clinical trials ( SUSTAIN ) demonstrated average HbA1c reductions of approximately 1.51.8% and body weight reductions of 69% in Type 2 diabetes populations
Rising Concern About Semaglutide and Eye Safety Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has become a cornerstone therapy for type 2 diabetes and weight management, with millions of patients benefiting from improved glycaemic control and cardiovascular outcomes
Future Outlook The GLP-1 Drug Market size is projected to reach USD 42.0 billion by 2035, growing at a CAGR of 13.17%, driven by increasing diabetes prevalence, rising obesity rates, and advancements in drug formulations
Weight loss typically begins within the first month, with significant results becoming apparent after 8-12 weeks of consistent use
However, it is hypothesized that the drug may work by decreasing appetite, slowing down gastric emptying, and potentially influencing the brains reward system
